Guidelines Panel Meeting: Salvage Therapy for Prostate Cancer (2023)

January 1, 2023 to April 18, 2023

Panel members will be reviewing evidence prepared and presented by a methodologist who has been extracting and analyzing data from research articles. The panelists will inquire about aspects of the evidence and the methodologists will provide explanations. The panel will discuss the evidence and deliberate on the best practice methods of salvage therapy for prostate cancer.

Target Audience

This activity is limited to Salvage Therapy for Prostate Cancer Guidelines Panel Members only. 

Learning Objectives

After completing this activity, participants will be able to:

  1. Analyze the latest scientific evidence for salvage therapy for of prostate cancer.
  2. Recommend appropriate methods of therapy for prostate cancer in the salvage setting.
  3. Apply improved critical thinking skills to medical literature reviews.
Course summary
Available credit: 
  • 9.00 AMA PRA Category 1 Credit™
  • 9.00 Non-Physician Participation
Course opens: 
Course expires: 
Event starts: 
01/01/2023 - 6:00am EST
Event ends: 
04/18/2023 - 11:59pm EDT

Tuesday, January 17th, 2023

6:00-6:10pm       Welcome and Introductions                                                                   Sennett Kim

6:10-6:20pm       Conflict of Interest Disclosures and Panel Responsibilities               Sennett Kim

6:20-8:45pm       OHSU Evidence Overview                                                                       Dr. Chou

8:45-9:00pm       Questions/Comments


Tuesday, March 21st, 2023

10:00-10:15am                 Introduction to review of Statement Development            Dr. Morgan, MD

10:15am-12:45pm            Guideline Statement Development                                       Panel

12:45-1:00pm                    Questions/Comments


Tuesday, April 11th, 2023

6:00-8:45pm       Continue Guideline Statement Development                                      Panel

8:45-9:00pm       Questions/Comments and Next Steps


*All Eastern Time

Guideline Panel Chair

NameCompany NameRelationship TypeEnd Date
Morgan, Todd MatthewMDxHealthScientific Study or Trial02/24/2022
Morgan, Todd MatthewMyriad GeneticsScientific Study or Trial12/31/2021
Morgan, Todd MatthewBlue EarthConsultant or Advisor02/28/2021
Morgan, Todd MatthewStratify GenomicsConsultant or Advisor03/03/2021
Morgan, Todd MatthewMyovant BiosciencesConsultant or Advisor11/01/2021
Morgan, Todd MatthewTempusConsultant or Advisor12/17/2021


NameCompany NameRelationship TypeEnd Date
Chou, RogerNothing to disclose  

COI Review Work Group

PDF icon COI Review Work Group Disclosures.pdf

AUA staff have nothing to disclose.

All relevant financial relationships have been mitigated. 

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 9.0 AMA PRA Category 1 Credit™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial (aka ineligible company) interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 9.00 AMA PRA Category 1 Credit™
  • 9.00 Non-Physician Participation
Please login or register to take this course.

Registration for this activity is limited to Salvage Therapy for Prostate Cancer Guideline Panel Members only.